Fluidigm (NASDAQ:FLDM) Issues Earnings Results, Misses Expectations By $0.08 EPS

Fluidigm (NASDAQ:FLDM) issued its quarterly earnings data on Thursday. The medical research company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.08), Bloomberg Earnings reports. Fluidigm had a negative net margin of 60.45% and a negative return on equity of 43.75%. The business had revenue of $28.20 million during the quarter, compared to analyst estimates of $30.16 million. Fluidigm’s revenue for the quarter was up 6.8% on a year-over-year basis. Fluidigm updated its Q3 2019 guidance to EPS.

Shares of Fluidigm stock traded down $4.10 during mid-day trading on Friday, hitting $8.05. 4,481,751 shares of the stock were exchanged, compared to its average volume of 600,747. Fluidigm has a twelve month low of $5.50 and a twelve month high of $14.90. The company has a market cap of $555.61 million, a PE ratio of -10.06 and a beta of 2.15. The stock has a 50-day moving average of $11.72. The company has a quick ratio of 2.86, a current ratio of 3.26 and a debt-to-equity ratio of 0.30.

In other Fluidigm news, Director Nicolas Barthelemy sold 5,100 shares of the firm’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $12.43, for a total transaction of $63,393.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Levin Easterly Partners Llc sold 186,759 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $12.31, for a total transaction of $2,299,003.29. The disclosure for this sale can be found here. Insiders have sold a total of 1,152,660 shares of company stock worth $13,815,948 over the last ninety days. 2.20% of the stock is owned by corporate insiders.

Several equities research analysts have issued reports on the stock. BidaskClub raised shares of Fluidigm from a “sell” rating to a “hold” rating in a research note on Friday, July 19th. Piper Jaffray Companies raised their price target on shares of Fluidigm from $14.00 to $16.00 and gave the stock an “overweight” rating in a research note on Friday, May 3rd. Zacks Investment Research raised shares of Fluidigm from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Wednesday, July 3rd. Finally, ValuEngine cut shares of Fluidigm from a “buy” rating to a “hold” rating in a research note on Wednesday, June 12th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $14.75.

About Fluidigm

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.

Further Reading: Cryptocurrencies

Earnings History for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.